NASDAQ · VYGR
Voyager Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VYGR: Nov 9, 2026
Voyager Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.41. The reported EPS for the same quarter last year was $-0.47.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.41 | $-0.29 | $-0.56 | 4 |
| Dec 2026 | $-0.34 | $-0.17 | $-0.49 | 4 |
| Mar 2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Jun 2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 21, 4:35 PM EDTVoyager Therapeutics, Inc. Appoints Robin Swartz as President and Outlines CEO Succession PlanVoyager Therapeutics, Inc. appointed Robin Swartz, the Company’s Chief Business Officer and Chief Operating Officer, to serve as President of the Company, effective October 20, 2026. Ms. Swartz is also expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D. as Chief Execut
- RTTNews · Oct 21, 11:02 AM EDTVoyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock Down(RTTNews) – Voyager Therapeutics Inc. (VYGR), a biotechnology company developing treatments for neurological diseases, said Wednesday Robin Swartz has been appointed president. Her appointment took effect on October 20, 2026.
- Zacks · Aug 6, 7:10 PM EDTVoyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 2, 5:08 AM EDTFDA Clears Voyager's IND For VY1706 In Alzheimer's Disease; Plans Trial Dosing In H2 2026(RTTNews) – Voyager Therapeutics, Inc. (VYGR), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application for VY1706, the company's investigational gene therapy for Alzheimer's disease.
- RTTNews · May 13, 7:58 AM EDTVoyager's VY1706 Cuts Tau In Single Dose; Alzheimer's Trial Set For H2 2026(RTTNews) – Voyager Therapeutics, Inc. (VYGR) reported new late-breaking data showing that a single intravenous dose of its investigational gene therapy VY1706 was well tolerated and produced meaningful reductions in tau protein in a three-month GLP toxicology study in non-human
- Zacks · May 7, 5:55 PM EDTVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of +12.96% and -74.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Mar 27, 10:28 AM EDTVoyager Therapeutics (VYGR) Price Target Increased by 12.22% to 17.17The average one-year price target for Voyager Therapeutics (NasdaqGS:VYGR) has been revised to $17.17 / share. This is an increase of 12.22% from the prior estimate of $15.30 dated February 21, 2026. The price target is an average of many targets provided by a
- Zacks · Mar 9, 5:15 PM EDTVoyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 5, 5:30 PM ESTLineage Cell (LCTX) Reports Break-Even Earnings for Q4Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 26, 9:55 AM ESTFortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag EstimatesFortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -42.82% and -1.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Nov 12, 7:05 PM ESTHC Wainwright & Co. Maintains Voyager Therapeutics (VYGR) Buy RecommendationFintel reports that on November 12, 2025, HC Wainwright & Co. maintained coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Buy recommendation. Analyst Price Forecast Suggests 275.12% Upside
- Zacks · Nov 10, 9:15 AM ESTVoyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue EstimatesVoyager Therapeutics (VYGR) delivered earnings and revenue surprises of +11.32% and +57.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Voyager Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.